Вопросы патогенеза и профилактики катастрофического антифосфолипидного синдрома в акушерской практике

1. Cervera R, Font J, Gomez-Puerta JA, Espinosa G et al.; Catastrophic Antiphospholipid Syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9.  
2. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508–12. 
3. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 2005;210:727–33.
4. Asherson RA, Cervera R, de Groot PG; Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530–4. 
5. Wiedermann FJ, Mayr A, Schobersberger W. Acute respiratory failure associated with catastrophic antiphospholipid syndrome. J Intern Med 2000;247:723–30.
6. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology. 2005;210:727–33.
7. Баркаган З.С., Момот А.П., Сердюк Г.В. Основы диагностики и терапии антифосфолипидного синдрома. М.: Ньюдиамед. 2003.
8. Насонов Е. Л. Антифосфолипидный синдром. М.: Литтера. 2004. 
9. Vora SK, Asherson RA, Erkan D. Catastrophic antiphospholipid syndrome. J Intensive Care Med. 2006; 21:144–59.
10. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome--molecular mimicry? J Rheumatol 2000;27:12–4. 
11. Gharavi AE, Pierangeli SS, Harris EN.New developments in viral peptides and APL induction. J Autoimmun. 2000;15:227–30. 
12. Raschi E, Testoni C, Bosisio D.Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood  2003;101:3495–500. 
13. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000;28:9–11
14. Asherson RA, Espinosa G, Cervera R et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 2005;64:943–46.
15. Karmochkine M, Mazoyer E, Marcelli A et. al. High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation. Thromb Haemost  1996;75:971. 
16. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996;5:488–93.
17. Lu CS, Horizon AA, Hwang KK. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005;52:4018–27. 
18. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998;104:381–5.
19. Yasuda S, Atsumi T, Matsuura E. Significance of valine/leucine247 polymorphism of β2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-β2-glycoprotein I autoantibodies to the valine247 β2-glycoprotein I variant.Arthritis Rheum 2005 Jan;52(1):212–8.
20. Katzav A, Evert T, Pick CG. Induction of antiphospholipid syndrome in Factor V Leiden mice. Immunobiology  2005;209:10–11. 
21. Brenner B, Hoffman R, Carp H et al.; LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost  2005;3:227–29.
22. Lai S, Walker DH, Elghetany MT. Catastrophic antiphospholipid syndrome: a rare cause of disseminated microvascular thrombotic injury – a case report with pathological and molecular correlative studies. Pathol Int  2005;55:144–49.
23. Makatsariya A., Asherson R.A., Bitsadze V., Baimuradova S., Akinshina S. Catastrophic antiphospholipid (asherson's) syndrome and genetic thrombophilic disorders in obstetrics. Autoimmun. Rev. 2006. Article in press.
24. Lu CS, Horizon AA, Hwang KK. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005;52:4018–27. 
25. Carmona F, Lazaro I, Reverter JC. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am J Obstet Gynecol  2006;194:457–65.
26. Le Thi Thuong D, Tieulie N. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005;64:273–8.
27. Bashiri A, Burstein E, Mazor M. Cerebral palsy and fetal inflammatory response syndrome: a review. J Perinat Med 2006;34(1):5–12.
28. Makatsariya A., Bitsadze V., Baimuradova S., Khizroeva D. K., Akinshina S. Fetal thrombophilia and obstetrics complications. Pathophysiology of haemostasis and thrombosis. Proceeding and abstracts from the 19th International Congress on Thrombosis. Tel-Aviv, Israel, May 140-18, 2006:A10.
29. Asherson RA. The catastrophic antiphospholipid syndrome (Asherson's syndrome). Monograph collected papers. 1992–2005. 
30. Bernard GR, Vincent JL, Laterre PF; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001. 344(10):699–709.
31. Erkan D, Leibowitz E, Berman J, Lockshin MD.Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol 2002; 29(4):843–9.

А.Д. Макацария, В.О. Бицадзе, С.В. Акиньшина

Кафедра акушерства и гинекологии медико-профилактического факультета ММА им. И. М. Сеченова,